98%
921
2 minutes
20
State-of-the-art therapy improves the five-year survival rate of patients under the age of 20 with cranial and craniospinal tumors by up to 74%. The urgency of dealing effectively with late treatment-associated cardiovascular complications is rising. : We aimed to assess echocardiographic parameters and exercise performance in subjects with a history of complex treatment for cranial and craniospinal tumors in childhood. : the study of 48 subjects who underwent cranial and craniospinal irradiation for CNS tumors in childhood and 20 healthy age- and sex-matched volunteers was conducted. The examination included hormone studies, cardiopulmonary exercise testing, and, in the main group, echocardiography (ECHO). In five (10.4%) patients, ECHO changes were detected after complex anti-cancer treatment: thickening and calcification of the aortic valve leaflets (2%), and reduction in the systolic LV and RV function (8% and 6%, respectively). Irradiation of various areas was a significant predictor for reduced exercise tolerance, hyperventilation at rest and upon exertion, and an increased ventilatory equivalent for carbon dioxide. Low exercise tolerance was associated with a younger age at the time of treatment initiation. Significant differences were noted between the control group and the childhood cancer survivors with endocrine disorders. The obtained data confirm the importance of regular cardiovascular and endocrine monitoring of this group of cancer survivors.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11173130 | PMC |
http://dx.doi.org/10.3390/jcm13113045 | DOI Listing |
J Neurooncol
September 2025
Department of Radiation Oncology, Massachusetts General Hospital, Boston, USA.
Purpose: Cranial irradiation is associated with health-related quality of life (HRQoL) deficits in childhood cancer survivors. We investigated the relationship between radiation dose to brain substructures and HRQoL in children with brain tumors treated with proton beam therapy (PBT).
Methods: Data were obtained from children in the Pediatric Proton/Photon Consortium Registry who received PBT for primary brain tumors between 2015 and 2021.
Imaging Neurosci (Camb)
July 2025
Univ Toulouse, CNRS, CerCo, Toulouse, France.
Growing evidence suggests that vascular abnormalities contribute to neurodegenerative processes during ageing. With the anticipated rise in the elderly population, we aimed to characterise arterial and venous flow dynamics, which reflect cardio-cerebro-vascular conditions, using a preclinical model: the marmoset monkey. We employed MRI protocols to image brain and intracranial vessel anatomy.
View Article and Find Full Text PDFCase Rep Oncol
June 2025
MedStar Georgetown Cancer Institute, Medstar Southern Maryland Hospital Center, Clinton, MD, USA.
Introduction: Sinonasal teratocarcinosarcoma (SNTCS) is an aggressive and highly recurrent tumor with a predilection for anterior skull base location. It continues to pose a challenge due to difficulty in diagnosis and the lack of large-scale studies on optimal treatment strategies.
Case Presentation: We report a case of a 48-year-old female patient who presented with headache, nausea, and vomiting.
J Appl Clin Med Phys
July 2025
Department of Radiation Oncology, Beijing Shijitan Hospital of Capital Medical University, Beijing, China.
Objective: The delivery quality assurance (DQA) of craniospinal irradiation (CSI) due to the target length results in no ideal verification devices. Delivery Analysis (DA) could calculate the dose distribution based on the measured multi leaf open time in helical tomotherapy (HT). This study aimed to evaluate the efficacy of DA for DQA of CSI in HT.
View Article and Find Full Text PDFJ Clin Med
June 2025
Neurosurgery Unit, Department of Neurosciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
Medulloblastoma represents a rare yet complex embryonal tumor of the posterior cranial fossa that, while predominantly affecting pediatric populations, occurs with increasing recognition among adolescents and young adults (AYAs, 15-39 years). The scarcity of medulloblastoma within this demographic creates substantial obstacles in diagnosis, treatment selection, and psychosocial management that differ markedly from established pediatric approaches. Emerging data reveal that AYA patients exhibit distinctive tumor biology, including altered molecular subgroup patterns, variable therapeutic responses, and unique survival trajectories when compared to younger patients.
View Article and Find Full Text PDF